BioMedNewsBreaks Archive - Page 207 of 223

TuesdayOct 13, 2020 12:12 pm

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Appoints Serial Entrepreneur as New Chief Operating Officer

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients who have high unmet medical needs, has appointed a new chief operating officer. Michael Floyd, a serial entrepreneur who has formed several life science organizations and served as a senior executive in those organizations, will be taking over that role. Floyd is well suited for the new position as many of the companies he has been involved in were focused on the development of products to treat infectious and rare diseases as well as the development of oncology drugs. Most recently,…

TuesdayOct 13, 2020 11:20 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Platform Selected for Integration in Vitality’s Gateway Flex

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics market, today announced that Vitality Group has chosen the company's digital therapeutics solutions for inclusion in Vitality's new Gateway Flex offering. According to the update, Gateway Flex enables employers to personalize the health-care experience to meet the diverse and rapidly changing needs of their employees and allows employers to pay only for solutions in which their employees engage. “We believe that our inclusion in Vitality's Gateway Flex offering represents another recent validation of our digital therapeutic solution and reinforces our position as a partner of choice,” Rick Anderson, president and general…

MondayOct 12, 2020 12:58 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. Files Registration Statement for Proposed $20M Initial Public Offering

Vivos Therapeutics, a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, on Friday announced that is has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its common stock. According to the update, application has been made for listing the common stock on the Nasdaq Capital Market under the ticker symbol “VVOS.” The proposed $20,000,000 offering (not including the underwriters’ over-allotment option), which is subject to market conditions with no assurance as to its actual completion or terms, has…

MondayOct 12, 2020 9:48 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights New Glioblastoma-Focused Segment Airing on Lifetime TV

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today highlighted a new segment from The Balancing Act titled, "Behind the Mystery," which will air on Lifetime TV and focus on glioblastoma. The segment, live this morning, follows the unique story of a glioblastoma patient and clinical insights regarding the rare and difficult-to-treat disease from Dr. Sigmund Hsu, a member of CNS Pharmaceuticals’ Scientific Advisory Board. In addition, a re-airing of the segment is planned for October 23, 2020. "It is encouraging to…

FridayOct 09, 2020 12:11 pm

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Simply Wall St Article

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products for patients with high unmet medical need conditions or no alternative treatment options, was featured in a Simply Wall St article. The piece highlights PCSA Co-Founder Patrick Lin’s recent stock purchase at near current price. The article reads, “Potential Processa Pharmaceuticals Inc. (NASDAQ: PCSA) shareholders may wish to note that the Co-Founder, Patrick Lin, recently bought US$125k worth of stock, paying US$4.00 for each share. While that's a very decent purchase to our minds, it was proportionally a bit modest, boosting their holding by just…

FridayOct 09, 2020 11:42 am

BioMedNewsBreaks – Cardiff Oncology Inc. (NASDAQ: CRDF) Announces Pricing of Underwritten Public Offering

Cardiff Oncology (NASDAQ: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, recently announced the pricing of its previously announced underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $13.50 per share. Cardiff Oncology anticipates receipt of approximately $88 million in gross proceeds from the offering, which is expected to close on or about October 2, 2020, subject to the satisfaction of customary conditions. The company has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares at…

FridayOct 09, 2020 11:09 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Begins Manufacturing of Lead Drug Candidate in Europe

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its European manufacturer, BSP Pharmaceuticals S.p.A. ("BSP"), has begun the manufacturing process for Berubicin Drug Product, its lead drug candidate for the treatment of glioblastoma multiforme (“GBM”). GBM is an aggressive form of brain cancer currently considered incurable. “Our preparations for filing an IND for Berubicin require continued execution in both our clinical and manufacturing initiatives,” CNS Pharmaceuticals CEO John Climaco said in the news release. “With the manufacturing of our…

ThursdayOct 08, 2020 3:21 pm

BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in Research Report

VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in a recent research report by Aegis Capital Corp. The report reads, “VistaGen is developing multiple therapeutic candidates for the treatment of anxiety, depression, and other CNS indications. VistaGen's development pipeline includes PH94B, a neuroactive nasal spray targeting Social Anxiety Disorder (‘SAD’), among other conditions, PH10, an additional neuroactive nasal spray for indications including Major Depressive Disorder (‘MDD’), and AV-101 an oral drug for psychiatric and other CNS disorders. We believe Phase 2 data in PH94B…

ThursdayOct 08, 2020 12:22 pm

BioMedNewsBreaks – CB Scientific Inc. (CBSC) Announces Thailand Launch of My-Cardia ECG Product Line, Services

CB Scientific (OTC: CBSC), engaged in providing innovative products and services for the ambulatory noninvasive cardiac monitoring space, today announced the targeted start of cardiac lab services operations in the country of Thailand through CBSC’s exclusive authorized distributor, Mango Wellness Co. Ltd. (“MWC”) and My Cardia Thailand Co. Ltd. (“MCT”), beginning Oct. 29, 2020. Under the agreement, MWC and MCT will be the exclusive distributor for CBSC’s proprietary FDA and CE-cleared EKG my-Cam Cardiac Event Monitor, the interactive cloud-based My-Cardia acquisition software, and the associated smartphone apps for both iOS and Android platforms in Thailand. The My-Cardia product line is…

WednesdayOct 07, 2020 2:46 pm

BioMedNewsBreaks – Why VistaGen Therapeutics (NASDAQ: VTGN) Is ‘One to Watch’

VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (“CNS”) disorders. Based out of South San Francisco, California, the “Birthplace of Biotechnology,” VistaGen is headquartered among the largest cluster of biotechnology companies in the world. A recent article discussing the company reads, “VistaGen currently has three innovative CNS drug candidates in its pipeline: PH94B, PH10 and AV-101. With a differentiated mechanism of action and an exceptional safety profile in all clinical studies to date, each of…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Appoints Serial Entrepreneur as New Chief Operating Officer

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Platform Selected for Integration in Vitality’s Gateway Flex

BioMedNewsBreaks – Vivos Therapeutics Inc. Files Registration Statement for Proposed $20M Initial Public Offering

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights New Glioblastoma-Focused Segment Airing on Lifetime TV

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Simply Wall St Article

BioMedNewsBreaks – Cardiff Oncology Inc. (NASDAQ: CRDF) Announces Pricing of Underwritten Public Offering

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Begins Manufacturing of Lead Drug Candidate in Europe

BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in Research Report

BioMedNewsBreaks – CB Scientific Inc. (CBSC) Announces Thailand Launch of My-Cardia ECG Product Line, Services

BioMedNewsBreaks – Why VistaGen Therapeutics (NASDAQ: VTGN) Is ‘One to Watch’

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search